Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 14

Inhaled Corticosteroids Prescribed for COPD Patients with Mild or Moderate Airflow Limitation: Who Warrants a Trial of Withdrawal?

Authors Harries TH, Gilworth G, Corrigan CJ, Murphy PB, Hart N, Thomas M, White PT

Received 12 November 2019

Accepted for publication 17 December 2019

Published 3 January 2020 Volume 2019:14 Pages 3063—3066

DOI https://doi.org/10.2147/COPD.S238239

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell


Timothy H Harries,1 Gill Gilworth,1 Christopher J Corrigan,2 Patrick B Murphy,3 Nicholas Hart,3 Mike Thomas,4 Patrick T White1

1Department of Public Health and Primary Care, School of Population Health and Environmental Sciences, King’s College London, London, UK; 2Department of Asthma Allergy and Respiratory Science, King’s College London, London, UK; 3Lane Fox Respiratory Unit, Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London, London, UK; 4Primary Care and Population Medicine, University of Southampton, Southampton, UK

Correspondence: Timothy H Harries
Department of Public Health and Primary Care, School of Population Health and Environmental Sciences, King’s College London 3rd Floor Addison House, Guys Campus, London SE1 1UL, UK
Tel +44 20 7836 5454
Email timothy.harries@kcl.ac.uk

Abstract: COPD patients prescribed inhaled corticosteroids (ICS) outside guidelines should be targeted for ICS withdrawal. Within a primary care population of 209,618 we used a combination of digital search algorithm, individual record review, and clinical review to identify COPD patients suitable for a trial of ICS withdrawal. At most, 39% of COPD patients with mild or moderate airflow limitation prescribed ICS were suitable for withdrawal according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Recurrent exacerbations and reversible airway obstruction were the main reasons for patients’ unsuitability for withdrawal. Identifying COPD patients in whom ICS withdrawal should be considered presents a challenge to primary care clinicians.

Keywords: pulmonary disease, chronic obstructive, inhaled corticosteroids, drug withdrawal, mild airflow limitation, moderate airflow limitation

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Download Article [PDF]  View Full Text [HTML][Machine readable]